Guidelines for conducting bridging studies in Alzheimer disease

Alzheimer Disease and Associated Disorders

Volumn 12, Issue 2, 1998, Pages 88-92

  Cutler, Neal R ^a   Sramek, John J ^a  

^a CALIFORNIA CLINICAL TRIALS   (United States)

Author keywords

Alzheimer disease; Bridging; Clinical trials; Phase I

Indexed keywords

PLACEBO; RIVASTIGMINE; VELNACRINE; XANOMELINE;

ADVERSE DRUG REACTION; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERANCE; HEALTH; HOSPITAL PATIENT; HUMAN; INFORMED CONSENT; META ANALYSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; TITRIMETRY; VOLUNTEER;

EID: 0032450451     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-199806000-00006     Document Type: Article

References (19)

1. Anand R, Enz A. Clinical confirmation of pre-clinical attributes: the ADENA program. Presented at the Fifth International Conference on Alzheimer's Disease and Related Disorders, Osaka, Japan, July 28, 1996.
2. Cutler NR, Murphy MF, Nash RJ, Prior PL, DeLuna DM. Clinical safety, tolerance, and plasma levels of the oral anticholinesterase 1,2,3,4-tetrahydro-9-aminoacridin-1-oL-maleate (HP 029) in Alzheimer's disease: preliminary findings. J Clin Pharmacol 1990;30:556-61.
3. Cutler NR, Sramek JJ. Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study. Eur J Clin Pharmacol 1995a;48: 421-8.
4. Cutler NR, Sramek JJ. The target population in phase I clinical trials of cholinergic compounds in Alzheimer disease: the role of the "bridging study." Alzheimer Dis Assoc Disord 1995b;9:139-45.
5. Cutler NR, Sramek JJ, Seifert RD, Sawin SF. The target population in phase I clinical trials of acetylcholinesterase inhibitors in dementia: the role of the "bridging study." In: Corain B, Iqbal M, Nicolini M, Winblad B, Wisniewski H, Aztta P, eds. Alzheimer's disease: advances in clinical and basic research. Sussex, England: John Wiley & Sons, 1993:559-62.
6. Cutler NR, Sramek JJ, Veroff AE. Alzheimer's disease: optimizing drug development strategies. Sussex, England: John Wiley & Sons, 1994.
7. Dayan AD. The limitations of animal studies: what can and cannot be predicted for man. Drug Info J 1991;25:165-70.
8. FDC Reports. Sandoz Exelon Alzheimer's treatment demonstrates no liver/kidney toxicity. FDC Rep Trade Gov Memos 1996;58(31):12.
9. Geller NL. Design of phase I and II clinical trials in cancer: a statistician's view. Cancer Invest 1984;2:483-91.
10. Murphy MF, Hardiman ST, Nash RJ, et al. Evaluation of HP 029 (velnacrine maleate) in Alzheimer's disease. Ann NY Acad Sci 1991;640:253-62.
11. Spilker B. Guide to clinical trials. New York: Raven Press, 1991:96-7.
12. Sramek JJ, Anand R, Wardle TS, Irwin P, Hartman RD, Cutler NR. Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease. Life Sci 1996;58:1201-7.
13. Sramek JJ, Block GA, Reines SA, Sawin SF, Barchowsky A, Cutler NR. A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase Life Sci 1994;56:319-26.
14. Sramek JJ, Hurley DJ, Wardle TS, et al. The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease. J Clin Pharmacol 1995a;35:800-6.
15. Sramek JJ, Sedman, AJ, Reece PA, et al. Safety and tolerability of CI-979 in patients with Alzheimer's disease. Life Sci 1995b;57:503-10.
16. Sramek JJ, Viereck C, Huff FJ, et al. A "bridging" (safety/tolerance) study of besipirdine hydrochloride in patients with Alzheimer's disease. Life Sci 1995c;57:1241-8.
17. Storer BE. Design and analysis of phase I clinical trials. Biometrics 1989;45:925-37.
18. Tollefson GD, Bodick NC, Shannon HC. Xanomeline: a potent and specific M1 agonist in the treatment of Alzheimer's disease. Presented at the annual meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 12-16, 1994.
19. Weissman L. Multiple-dose phase I trials - normal volunteers or patients? One viewpoint. J Clin Pharmacol 1981;21:385-7.